Orchard Therapeutics Announces That OTL-101 Has Received a Designation as Promising Innovative Medicine by UK’s Regulatory Agency

Uncategorized August 24, 2017 at 10:27 AM 0 comments

London, UK, 22 August, 2017 – Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company developing transformative gene therapies for patients with severe inherited orphan diseases, today announces that the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) granted a Promising Innovative Medicine Designation to OTL-101, its lead programme for theRead More

Introducing EMJ Reproductive Health 3.1

Introducing EMJ Reproductive Health 3.1

Reproductive Health August 17, 2017 at 8:57 AM 0 comments

United Kingdom, August 17, 2017: A warm welcome to the 2017 EMJ Reproductive Health eJournal! This instalment gives a complete review of the much-anticipated European Society of Human Reproduction and Embryology (ESHRE) congress, this year held in Geneva, Switzerland, from 2nd–5th July. Subjects discussed there spanned ovarian rejuvenation, germline geneRead More

The University of Huddersfield’s Pressure Ulcer Experts Team up Bruin Biometrics Based in Los Angeles

The University of Huddersfield’s Pressure Ulcer Experts Team up Bruin Biometrics Based in Los Angeles

Innovations August 11, 2017 at 11:33 AM 0 comments

The strategic alliance will focus on the use of the SEM scanner early detection technology to attack the UK’s £2 billion+ health problem 9 August, 2017 – An innovative research collaboration between the University of Huddersfield and the Los Angeles-based medical device company Bruin Biometrics (BBI, LLC) has been revealed. ExpertsRead More

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

Hematology, Oncology August 3, 2017 at 1:54 PM 0 comments

Randomized, double-blind, placebo-controlled study to enroll up to 500 patients worldwide Lugano, Switzerland and San Diego, USA, 2 August, 2017 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapiesRead More

Introducing EMJ Allergy & Immunology 2.1

Introducing EMJ Allergy & Immunology 2.1

Allergy & Immunology August 3, 2017 at 8:45 AM 0 comments

United Kingdom, August 03, 2017: EMJ would like to welcome you to the latest edition of EMJ Allergy and Immunology. This much-anticipated eJournal contains a comprehensive summary of the 61st Annual Meeting of the European Academy of Allergy and Clinical Immunology Congress (EACCI), as well as a selection of outstandingRead More

Introducing EMJ Rheumatology 4.1

Introducing EMJ Rheumatology 4.1

Rheumatology August 1, 2017 at 8:41 AM 0 comments

United Kingdom, August 01, 2017: A warm welcome to EMJ Rheumatology 4.1, a journal that aims to bring healthcare professionals up to date on the latest advances in this fast-paced field. Inside this eJournal the reader will find an independent review of the European League Against Rheumatism (EULAR) Annual EuropeanRead More

Neurodegeneration Biomarkers for Diagnosis of Alzheimer’s and MND

Neurology July 26, 2017 at 8:57 AM 0 comments

EUROIMMUN Press Release 26 July, 2017 – A portfolio of CSF biomarkers corresponding to different stages of the neurodegenerative process aids diagnosis of Alzheimer’s disease (AD) and motor neuron diseases (MND). The classic AD markers beta amyloid and tau measure aggregates like plaques and tangles. The most reliable measure ofRead More

Comprehensive Serological Diagnostics in Neurology

Neurology July 26, 2017 at 8:55 AM 0 comments

EUROIMMUN Press Release 26 July, 2017 – Neurological disorders, including memory deficits, psychosis and seizures, can be caused by underlying autoimmune reactions. In unexplained neurological cases, autoantibody testing can help establish a diagnosis of e.g. anti-NMDAR encephalitis, paraneoplastic syndrome (PNS) or neuromyelitis optica. EUROIMMUN has developed a comprehensive range of assaysRead More

ANTABIO Awarded Up to $8.9M from CARB-X to Accelerate the Development of Its New Treatment For Chronic Infections in Cystic Fibrosis Patients

Respiratory July 25, 2017 at 2:21 PM 0 comments

Labège, France, 25 July, 2017 – Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world’s largest public-private partnership devoted to antibacterial R&D. Antabio was selected by CARB-XRead More

Orchard Therapeutics Announces That OTL-101 Has Received a Rare Paediatric Disease Designation

Uncategorized July 24, 2017 at 5:14 PM 0 comments

London, UK, 24 July, 2017 – Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to bringing transformative autologous ex-vivo gene therapies to patients with rare diseases of high unmet medical need is delighted to announce today that the US Food and Drug Administration (FDA) granted a Rare Paediatric DiseaseRead More